Amgen's Enbrel Does Not Infringe Ariad Patent: Judge

Law360, New York (September 22, 2008, 12:00 AM EDT) -- A Delaware judge on Friday granted Amgen Inc. summary judgment of noninfringement in a “convoluted” patent case against Ariad Pharmaceuticals Inc. over an arthritis treatment patent.

"There is no genuine issue of material fact concerning Ariad's infringement claims," wrote Judge Mary Pat Thynge in U.S. District Court for the District of Delaware.

Amgen sought confirmation that the heavily litigated patent – U.S. Patent No. 6,410,516 – for cell-signaling activity is not infringed by Amgen's popular anti-arthritis drug Enbrel.

“We are pleased the court ruled in Amgen’s...
To view the full article, register now.